[{"data":1,"prerenderedAt":439},["ShallowReactive",2],{"tool-healthcare-taimei":3,"footer-total":412,"related-healthcare-taimei":413},{"id":4,"title":5,"author":6,"bestFor":7,"body":8,"category":369,"cons":370,"cover":376,"date":377,"description":378,"draft":379,"extension":380,"meta":381,"navigation":382,"notFor":383,"path":384,"pricing":385,"pros":389,"region":395,"score":396,"scoreBreakdown":397,"seo":403,"stem":404,"tags":405,"toolName":234,"updated":377,"url":409,"vendor":410,"__hash__":411},"tools\u002Ftools\u002Fhealthcare\u002Ftaimei.md","太美医疗 评测","元析评测","每年运行十个以上注册类试验的药企、CRO,以及有国际合作项目的临床研究机构",{"type":9,"value":10,"toc":341},"minimark",[11,15,23,26,29,69,72,77,80,83,87,90,93,97,100,103,107,110,113,116,120,123,127,130,134,137,141,144,148,151,154,217,220,223,298,304,308,312,315,319,322,326,329,332,335],[12,13,14],"h2",{"id":14},"结论先行",[16,17,18,22],"p",{},[19,20,21],"strong",{},"推荐,总分 8.1,官网未公开报价,走项目制签约。"," 太美医疗把临床试验拆成二十多个系统,核心是四条:EDC 采数据、CTMS 管项目、eTMF 存文档、eSafety 报安全性事件。一个注册类试验从立项到锁库,数据与文档在同一套体系里流转,稽查时不用满世界找版本。",[16,24,25],{},"它不适合小规模用户。按试验和中心计费的模式,一年跑十个试验的团队摊下来合算,一年跑一个的科室就会发现平台费比试验本身还贵。买之前先算清一件事:你一年有多少试验真正需要结构化数据管理。",[12,27,28],{"id":28},"这篇评测基于什么数据",[30,31,32,39,48,54,63],"ul",{},[33,34,35,38],"li",{},[19,36,37],{},"官网",":2026-11 核对 taimei.com 首页与产品导航,取得产品名录、公司规模数据(1600+ 客户、10000+ 试验、30+ 国家\u002F地区、3 个数据中心)与联系方式。",[33,40,41,44,47],{},[19,42,43],{},"产品清单",[45,46],"e-clinical",{}," 线含 eCollect(EDC)、eCooperate(CTMS)、eArchives(eTMF)、eBalance(RTSM)、eOutcome(eCOA)、eCollege、IIT-EDC、eSite、eTrial、eScreening;另有 eSafety 药物警戒、iMAP 医学分析、终点评估与数智营销产品。",[33,49,50,53],{},[19,51,52],{},"法规口径",":《药物临床试验质量管理规范》自 2020-07-01 施行,对电子源数据、稽查轨迹、数据修改留痕有明确要求;国际多中心试验还要对齐 ICH E6 与 21 CFR Part 11。",[33,55,56,59,62],{},[19,57,58],{},"数据标准",[60,61],"cdisc",{}," SDTM 与 ADaM 是递交数据的通用格式,EDC 建库字段设计要能直接映射过去。",[33,64,65,68],{},[19,66,67],{},"实测声明",":我们没有实际建过一个试验库,没走过稽查轨迹导出,也没有拿到报价单。以下判断来自官网信息、公开资料与同类系统的普遍规律。",[12,70,71],{"id":71},"核心功能",[73,74,76],"h3",{"id":75},"edc试验数据的地基","EDC:试验数据的地基",[16,78,79],{},"eCollect 是 EDC,负责把病例报告表变成电子表单。研究者录入、系统做逻辑校验、数据管理员发质疑、中心回复,这条循环决定了试验数据的干净程度。",[16,81,82],{},"关键在稽查轨迹。谁在什么时间改了哪一格、改前是什么、改后是什么、为什么改,必须完整留痕且不可删除。国内核查看过不少因为轨迹不全被要求补充说明的案例,这块做不好,后面全是被动。",[73,84,86],{"id":85},"ctms-与-etmf项目与文档","CTMS 与 eTMF:项目与文档",[16,88,89],{},"eCooperate 管项目进度:中心启动、入组速度、访视完成率、稽查计划。eArchives 管试验主文档,把方案、伦理批件、研究者简历、培训记录按 DIA 参考模型归档。",[16,91,92],{},"文档这块的痛点是版本。方案改了三次,中心手里还拿着第一版,监查员跑一趟才发现。系统用文件树加版本号约束,至少能让\"现在该用哪一版\"有唯一答案。",[73,94,96],{"id":95},"esafety药物警戒","eSafety:药物警戒",[16,98,99],{},"药物警戒管的是安全性事件:个例报告收集、编码(MedDRA)、评估、按法规时限上报。严重不良事件通常要求 24 小时内报告,迟报是常见扣分项。",[16,101,102],{},"MedDRA 编码是门槛,需要专门培训。系统能做的是把编码建议、时限提醒、报告生成自动化,判断仍要人来做。",[73,104,106],{"id":105},"ai-智能体与终点评估","AI 智能体与终点评估",[16,108,109],{},"导航里的 iDM、iCTA、iPV 分别指向数据管理、临床试验供应、药物警戒三个场景,思路是把重复劳动先让模型跑一遍:比如自动生成建库草案、自动从病历里抽取不良事件描述。",[16,111,112],{},"另外两块值得单说:iMAP 做医学监查,把安全性数据可视化以便及早发现异常信号;终点评估提供独立影像评估(IRC),肿瘤试验里常见的盲态独立中心评估就走这条线。",[12,114,115],{"id":115},"评分明细",[73,117,119],{"id":118},"功能完整度8910","功能完整度:8.9\u002F10",[16,121,122],{},"从建库、项目管理、文档归档到安全性上报,链条上没有明显断点,边角系统(查重、机构管理、一期病房)也补齐了。扣分在真实世界研究与上市后研究,这块比专做数据的厂商浅。",[73,124,126],{"id":125},"易用性7610","易用性:7.6\u002F10",[16,128,129],{},"研究者端做了一定简化,常用表单能一屏填完。扣分在角色多:研究者、CRC、CRA、DM、PV 各有各的界面,新人要按角色分别培训,中心端配合差的时候体验很差。",[73,131,133],{"id":132},"数据质量8710","数据质量:8.7\u002F10",[16,135,136],{},"逻辑校验、质疑管理、稽查轨迹、编码字典都到位,导出能直接对齐 CDISC。扣分在跨系统一致性:EDC 与 eTMF 的版本一旦不同步,核查时会出现对不上的情况。",[73,138,140],{"id":139},"性价比6910","性价比:6.9\u002F10",[16,142,143],{},"单价不低,按试验与中心计费,试验少的机构摊不下来。国产替代的空间在于比国际厂商便宜,但和国内小厂比仍然贵,采购时要按三年总成本算,不能只看首年。",[73,145,147],{"id":146},"客户支持8310","客户支持:8.3\u002F10",[16,149,150],{},"有 400 电话与专属对接,实施期会配建库与培训,国际多中心项目有本地团队。扣分在响应分层:紧急问题处理快,需求类问题要排队到下个版本。",[12,152,153],{"id":153},"定价说明",[155,156,157,173],"table",{},[158,159,160],"thead",{},[161,162,163,167,170],"tr",{},[164,165,166],"th",{},"项目",[164,168,169],{},"价格",[164,171,172],{},"说明",[174,175,176,188,198,208],"tbody",{},[161,177,178,182,185],{},[179,180,181],"td",{},"EDC 单试验授权",[179,183,184],{},"未公开",[179,186,187],{},"按试验规模、中心数、表单量计价",[161,189,190,193,195],{},[179,191,192],{},"CTMS 与 eTMF",[179,194,184],{},[179,196,197],{},"可按年度平台授权或按项目计价",[161,199,200,203,205],{},[179,201,202],{},"eSafety 药物警戒",[179,204,184],{},[179,206,207],{},"按报告数量与年度订阅计价",[161,209,210,212,214],{},[179,211,106],{},[179,213,184],{},[179,215,216],{},"新上线模块,按调用量或项目打包",[16,218,219],{},"2026-11 核对时,官网二十多个产品入口没有一个标价,全部导向\"申请试用\"。这类系统报价差异主要来自三处:试验数量、中心数量、是否含建库与数据管理服务。签约前建议把三件事写清:单个试验的授权上限(超期是否加钱)、新增中心的单价、以及锁库后数据导出的格式与费用。",[12,221,222],{"id":222},"和竞品对比",[155,224,225,241],{},[158,226,227],{},[161,228,229,232,235,238],{},[164,230,231],{},"维度",[164,233,234],{},"太美医疗",[164,236,237],{},"Medidata",[164,239,240],{},"百奥知",[174,242,243,257,270,284],{},[161,244,245,248,251,254],{},[179,246,247],{},"定位",[179,249,250],{},"临床研发全链条平台",[179,252,253],{},"全球主流 EDC 与临床数据平台",[179,255,256],{},"国内 eClinical 与注册服务",[161,258,259,262,265,268],{},[179,260,261],{},"起步价",[179,263,264],{},"未公开,项目制",[179,266,267],{},"未公开,按试验与用户计",[179,269,264],{},[161,271,272,275,278,281],{},[179,273,274],{},"强项",[179,276,277],{},"产品全、国内合规适配好",[179,279,280],{},"国际多中心认可度高",[179,282,283],{},"价格灵活、本土服务快",[161,285,286,289,292,295],{},[179,287,288],{},"短板",[179,290,291],{},"国际品牌认知弱",[179,293,294],{},"成本高、国内落地支持薄",[179,296,297],{},"产品线窄、国际项目少",[16,299,300,303],{},[19,301,302],{},"怎么选",":试验主要在国内、还要覆盖药物警戒与影像评估,太美医疗一家能供完;试验要在欧美同步申报、申办方是跨国药企,Medidata 的接受度更高;预算有限、只要 EDC 加注册申报支持,百奥知的报价更灵活。",[12,305,307],{"id":306},"faq","FAQ",[73,309,311],{"id":310},"q-一年只做两三个试验用得着这么重的平台吗","Q: 一年只做两三个试验,用得着这么重的平台吗?",[16,313,314],{},"A: 单看成本不划算。试验少的时候,可以用轻量 EDC 加共享文件盘过渡,等年试验数上到五个以上、或者要应付核查,再上平台。反过来说,如果试验数据要用于注册申报,稽查轨迹这条底线不能省。",[73,316,318],{"id":317},"q-稽查轨迹能应付药监核查吗","Q: 稽查轨迹能应付药监核查吗?",[16,320,321],{},"A: 系统能提供完整轨迹,但能不能过核查看的是使用习惯。常见问题是中心把数据先记在纸上再集中录入,轨迹上就看不出\"实时采集\"。想避免,得在方案和培训里明确要求源数据即时录入。",[73,323,325],{"id":324},"q-数据存在境外服务器上合规吗","Q: 数据存在境外服务器上,合规吗?",[16,327,328],{},"A: 要看数据类型与流向。官网写明数据中心分设中国、新加坡、美国,国内试验的数据应留在境内;涉及人类遗传资源的信息出境要按《人类遗传资源管理条例》办理手续。签合同前把数据存储位置、备份策略、跨境传输条款逐条确认。",[12,330,331],{"id":331},"评测方法说明",[16,333,334],{},"元析评测围绕功能完整度、易用性、数据质量、性价比、客户支持五个维度打分,每项满分 10 分,加权折算总分。本篇的产品名录与公司规模数据核对于 2026-11 官网;官网未公示价格,文中不含任何金额,实际报价以项目方案与合同为准。",[16,336,337,340],{},[19,338,339],{},"最后更新",":2026-11-16",{"title":342,"searchDepth":343,"depth":343,"links":344},"",2,[345,346,347,354,361,362,363,368],{"id":14,"depth":343,"text":14},{"id":28,"depth":343,"text":28},{"id":71,"depth":343,"text":71,"children":348},[349,351,352,353],{"id":75,"depth":350,"text":76},3,{"id":85,"depth":350,"text":86},{"id":95,"depth":350,"text":96},{"id":105,"depth":350,"text":106},{"id":115,"depth":343,"text":115,"children":355},[356,357,358,359,360],{"id":118,"depth":350,"text":119},{"id":125,"depth":350,"text":126},{"id":132,"depth":350,"text":133},{"id":139,"depth":350,"text":140},{"id":146,"depth":350,"text":147},{"id":153,"depth":343,"text":153},{"id":222,"depth":343,"text":222},{"id":306,"depth":343,"text":307,"children":364},[365,366,367],{"id":310,"depth":350,"text":311},{"id":317,"depth":350,"text":318},{"id":324,"depth":350,"text":325},{"id":331,"depth":343,"text":331},"healthcare",[371,372,373,374,375],"官网没有一个价格数字,预算只能靠销售给方案,早期立项估算很难做","产品线二十多个,采购时容易买重,模块边界要靠实施顾问画清楚","系统学习成本不低,研究者与 CRC 要培训,中心端配合度差会拖慢入组","按试验与中心计费,试验数量少的机构摊不下来,单试验成本偏高","AI 智能体功能上线时间不长,实际节省的人力还需要在项目里验证",null,"2026-11-16","太美医疗评测:官网未公开报价,按试验数与模块项目制签约,EDC、CTMS、eTMF 加药物警戒是一条完整临床研发链。适合每年跑十个以上试验的药企与 CRO,不适合只做单个 IIT 的科室。",false,"md",{},true,"一年只做一两个研究者发起试验(IIT)的科室,或预算极紧的初创团队","\u002Ftools\u002Fhealthcare\u002Ftaimei",{"free":379,"startingPrice":342,"currency":386,"billingPeriod":387,"notes":388},"CNY","一次性","官网未公开报价,需联系销售。2026-11 核对 taimei.com 首页与产品导航,导航里列出二十余个产品入口,均无价格页,只有「申请试用」与 400-699-1906 咨询电话。此类系统按试验数量、启用模块、中心数与服务年限报价,单试验授权与年度平台授权是两种常见计费方式。2026-11 核对。",[390,391,392,393,394],"官网写明 2013 年起做临床开发,1600+ 客户、10000+ 试验在其平台运行,3 个数据中心分设中国、新加坡、美国","EDC、CTMS、eTMF、药物警戒四条主线齐全,一个试验的数据、文档、安全报告能在同一平台里串起来","受试者查重、机构管理、一期病房管理这些边角系统都有独立产品,不用再找第三家补","导航里已挂出四个 AI 智能体(iDM、iCTA、iPV 等),把重复的建库、监查、个例报告工作交给模型先做一遍","覆盖 30 多个国家\u002F地区,多中心国际试验的合规与语言适配不用从零搭","cn",8.1,{"features":398,"ease":399,"data":400,"price":401,"support":402},8.9,7.6,8.7,6.9,8.3,{"title":5,"description":378},"tools\u002Fhealthcare\u002Ftaimei",[406,407,408,234],"医疗健康","临床试验","EDC","https:\u002F\u002Fwww.taimei.com","浙江太美医疗科技股份有限公司","rjpl6XD6KoGyczAOq-q0uK_TQBqZPas1_P4w6DH6MWs",1016,[414,424,432],{"path":415,"toolName":416,"description":417,"score":418,"pricing":419,"vendor":422,"date":423,"category":369},"\u002Ftools\u002Fhealthcare\u002Fdxy","丁香医生","丁香医生是丁香园旗下院外健康平台,集团官网写明注册医师 450 万+,App 首次问诊 9.9 元起,科普内容有医生审稿。它适合药企做患者教育、个人问小病,不适合当医院信息系统用,也不做医保结算,问诊只是轻咨询。",8.6,{"free":382,"startingPrice":342,"currency":386,"billingPeriod":420,"notes":421},"年","C 端免费使用,问诊按次付费,App Store 官方文案写明首次问诊 9.9 元起,复诊单价由接诊医生设定。药企内容合作、医院科普项目等机构业务官网未公开标准报价,需联系销售。价格核对时间 2026-11。","丁香园","2026-11-04",{"path":425,"toolName":426,"description":427,"score":428,"pricing":429,"vendor":426,"date":431,"category":369},"\u002Ftools\u002Fhealthcare\u002Falihealth","阿里健康","阿里健康是阿里系医药与医疗平台,官网披露天猫健康 4.83 万商家、大药房 123 万 SKU、码上放心服务 7100 家流通企业。强项在商家规模与药品追溯合规,适合药企做渠道,不适合想买独立 HIS 的医院,云医院由合作方实施。",8.5,{"free":379,"startingPrice":342,"currency":386,"billingPeriod":420,"notes":430},"C 端购药与问诊按件、按次付费,无独立订阅套餐。天猫健康入驻涉及保证金与技术年费,码上放心按追溯码用量或年度服务计费,官网均未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-22",{"path":433,"toolName":434,"description":435,"score":402,"pricing":436,"vendor":434,"date":438,"category":369},"\u002Ftools\u002Fhealthcare\u002Fhaodf","好大夫在线","好大夫在线收录 10450 家医院、931617 位大夫,App 写明 28 万医生入驻、服务 8900 万患者。它是医生个人品牌的入口,问诊价格由医生定,适合副主任以上医生和找专病专家的患者。不适合急诊,入驻免费但抽成不公开,签约前要多看同城案例。",{"free":382,"startingPrice":342,"currency":386,"billingPeriod":420,"notes":437},"患者浏览医生主页、看评价免费,图文、电话、视频问诊按医生自报价付费,私人医生与优选会员为付费服务。医生入驻不收费。平台抽成比例与机构合作报价官网未公开标准报价,需联系销售。价格核对时间 2026-11。","2026-10-29",1794788232889]